Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Halozyme Therapeutics Incorporated | HALO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 19.55 | 0.00 | 0.00 | 0.00 | 19.55 | 06:59:40 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 18.55 | 21.50 | 2.95 | 13.72% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Halozyme Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 2.67B | 136.70M | $ -80.33M | -0.55 | -66.18 | 125.65M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Halozyme Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HALO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 20.28 | 20.7448 | 19.37 | 19.88 | 1,533,358 | -0.73 | -3.6% |
| 1 Month | 18.38 | 21.00 | 17.53 | 19.09 | 1,327,689 | 1.17 | 6.37% |
| 3 Months | 15.35 | 21.00 | 14.15 | 18.33 | 1,901,271 | 4.20 | 27.36% |
| 6 Months | 16.49 | 21.00 | 14.15 | 17.63 | 1,237,783 | 3.06 | 18.56% |
| 1 Year | 15.93 | 21.00 | 14.15 | 17.15 | 1,015,489 | 3.62 | 22.72% |
| 3 Years | 11.50 | 21.48 | 10.79 | 16.50 | 1,032,105 | 8.05 | 70.0% |
| 5 Years | 13.81 | 25.25 | 6.96 | 14.93 | 1,191,764 | 5.74 | 41.56% |
Halozyme Therapeutics Description
| Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
